For instance, inhibitors of PTHrP signaling, or agents that block RANKL, such as denosumab, have shown promise in reducing skeletal‐related events in cancer patients by decreasing bone turnover and preserving bone integrity [38]. This evidence concerns the gene PTHLH and cancer.